We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-1.01%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.36B
AUM Growth
-$447M
Cap. Flow
-$196M
Cap. Flow %
-4.5%
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
20

Top Buys

1
LLY icon
Eli Lilly
LLY
+$183M
2
ARGX icon
argenx
ARGX
+$128M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$108M
4
JNJ icon
Johnson & Johnson
JNJ
+$97.3M
5
HUM icon
Humana
HUM
+$95M

Top Sells

1
MRK icon
Merck
MRK
+$194M
2
BAX icon
Baxter International
BAX
+$149M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$146M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$115M
5
ABBV icon
AbbVie
ABBV
+$109M

Sector Composition

1 Healthcare 95.35%
2 Financials 0.54%
3 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
26
Legend Biotech
LEGN
$4.31B
$55M 1.26%
1,000,000
-95,000
-9% -$4.01M
ARWR icon
27
Arrowhead Research
ARWR
$10.5B
$50.7M 1.16%
1,438,999
+483,999
+51% +$18.2M
IMCR icon
28
Immunocore
IMCR
$1.78B
$50.4M 1.16%
1,350,000
-13,800
-1% -$448K
NTRA icon
29
Natera
NTRA
$38.9B
$48.5M 1.11%
1,369,100
+69,100
+5% +$2.56M
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$44.3M 1.02%
+775,504
New +$44M
IDYA icon
31
IDEAYA Biosciences
IDYA
$3.47B
$41M 0.94%
2,972,947
+282,947
+11% +$3.15M
BLU
32
DELISTED
BELLUS Health Inc.
BLU
$39.4M 0.9%
4,265,000
+580,000
+16% +$4.74M
ALT icon
33
Altimmune
ALT
$558M
$34.9M 0.8%
2,981,000
+116,000
+4% +$715K
KZR
34
DELISTED
Kezar Life Sciences
KZR
$33.5M 0.77%
405,000
+53,200
+15% +$4.69M
RNAM
35
DELISTED
Avidity Biosciences
RNAM
$30.2M 0.69%
2,080,200
+35,200
+2% +$524K
KRTX
36
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$25.9M 0.59%
+204,570
New +$23.5M
RVMD icon
37
Revolution Medicines
RVMD
$39.6B
$25.8M 0.59%
+1,325,000
New +$25.8M
ARKG icon
38
ARK Genomic Revolution ETF
ARKG
$1.61B
$23.6M 0.54%
+750,000
New +$26.2M
VIR icon
39
Vir Biotechnology
VIR
$1.59B
$19.3M 0.44%
758,211
-21,789
-3% -$509K
NKTX icon
40
Nkarta
NKTX
$186M
$17.4M 0.4%
+1,414,082
New +$18.6M
PHAT icon
41
Phathom Pharmaceuticals
PHAT
$873M
$16.2M 0.37%
1,919,800
-26,200
-1% -$269K
CRBU icon
42
Caribou Biosciences
CRBU
$165M
$16M 0.37%
2,950,000
+130,933
+5% +$1M
DCPH
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$15.8M 0.36%
+1,200,000
New +$13.2M
NUVB icon
44
Nuvation Bio
NUVB
$2.02B
$15.7M 0.36%
4,855,000
-6
-0% -$26
IOVA icon
45
Iovance Biotherapeutics
IOVA
$2.23B
$15.4M 0.35%
1,392,300
-4,650,919
-77% -$60.9M
XENE icon
46
Xenon Pharmaceuticals
XENE
$6.6B
$13.7M 0.31%
+450,000
New +$13.6M
SIBN icon
47
SI-BONE Inc
SIBN
$771M
$13.2M 0.3%
1,000,000
– –
SPNE
48
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$11.4M 0.26%
2,010,000
– –
ATEC icon
49
Alphatec Holdings
ATEC
$1.31B
$11.2M 0.26%
1,715,000
-1,020,600
-37% -$9.4M
APLS
50
DELISTED
Apellis Pharmaceuticals
APLS
$9.72M 0.22%
215,000
+5,000
+2% +$228K
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
CM
Columbus Macro New Castle, Pennsylvania $936M AUM 12.9% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return

Avidity Partners Management's Q2 2022 Portfolio in Review

As of Q2 2022, Avidity Partners Management held 102 positions worth $4.36B, down 9.3% from $4.8B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management withdrew a net $196M in Q2 2022, closing 20 positions and reducing 13 holdings. Its most notable exit was Merck, an estimated $194M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Financials and Technology.

Against the trend, Avidity Partners Management opened a new position in Eli Lilly worth $198M.

  • Avidity Partners Management's largest Q2 2022 buy was Eli Lilly: 610,000 shares worth $198M.
  • Avidity Partners Management added most to argenx in Q2 2022, an estimated $128M increase.
  • Avidity Partners Management's biggest Q2 2022 reduction was AbbVie, cutting an estimated $109M.
  • Avidity Partners Management fully exited Merck in Q2 2022, selling an estimated $194M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $4.36B portfolio in Q2 2022.
  • Avidity Partners Management opened 10 new positions and closed 20 in Q2 2022.
  • Avidity Partners Management's portfolio value fell 9.3% quarter-over-quarter to $4.36B.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.